236 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (223)
- Addiction (6)
- Autoimmune Disorders (15)
- Blood Disorders (23)
- Bone & Muscle (1)
- Cancer (3)
- Child Development (1)
- Endocrine & Metabolic Disease (2)
- Hair and Skin Disorders (2)
- Healthy Volunteers (8)
- Heart Disease (1)
- Liver Disease (1)
- Lung Disease (1)
- Meniere's Disease (1)
- Neurological Disorders (102)
- Obstetrics & Gynecology (3)
- Pediatrics (5)
- Psychiatric Disorders (48)
Displaying 1 - 14 of 14
Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Currently Recruiting
This is a global, multicenter, placebo-controlled, phase 3 study evaluating the efficacy and safety of riliprubart in adult participants with CIDP who are refractory or had an insufficient response to standard of care (SOC) therapies, defined as Ig administered IV (IVIg) or SC (SCIg), or corticosteroids. Treatment duration will be 48 weeks. Participant must…
Condition: Psychiatric Disorders / Anxiety
Investigator: Franklin Schneier, MD
Status: Closed
We are currently enrolling individuals with social anxiety disorder to participate in this study. The purpose of this study is to assess whether a brief computer-based research treatment helps improve social anxiety symptoms. For eligible participants, this study will involve a brief, novel research treatment for social anxiety, delivered in 8 or 12…
Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
Subjects with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) will be enrolled in the study and Intravenous Immunoglobulin (IVIg) will be given to eligible subjects on the study. CIDP is a chronic inflammatory condition that causes the immune system to attack the nerves. IVIg is one common treatment for CIDP. IVIG is a blood product that is…
Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to evaluate the efficacy and safety of study drug, fingolimod taken daily compared with a placebo (does not contain active medication) on delaying disability progression in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The study will consist of 3 periods: a Screening Period (lasting for up to 45…
Condition: Psychiatric Disorders / Anxiety
Investigator: Amir Levine, MD
Status: Closed
Sertraline (also known as Zoloft) is an FDA approved medication that is used to treat anxiety in children and adolescents. We aim to better understand how children and adolescents with anxiety respond to sertraline and whether we can predict medication response. If your child is eligible, he or she can participate in a research study and will receive both a…
Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to see how effective two doses of an investigational new drug called IgPro20 is when given subcutaneously (a shot given into the fat layer between the skin and the muscle) to treat CIDP in patients that still require IVIG and also to look at how safe the IgPro20 is for patients.
Condition: Psychiatric Disorders / Anxiety
Investigator: Franklin Schneier, MD
Status: Closed
RESEARCH STUDY:Brief Intervention for Public Speaking Fears (IRB#7293).- Are you between the ages of 18 - 60?- Do you have bothersome fears of public speaking?- Are you interested in trying a novel intervention?This research study tests whether a brief intervention using a medication called propranolol is effective at reducing public speaking fears. This…
Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to collect information about how patients with FAP respond to the study drug ALN-TTR02 over 18 months. This includes studying any potential improvements in FAP and any side effects that participants may have from the study drug. In addition, the study will examine how the body handles (distributes, break down, eliminates) the…
Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
Peripheral Neuropathy is a result of nerve damage, which may cause weakness, numbness, tingling, and pain in your hands, feet, and other areas of your body. Over 20 million Americans are affected by peripheral neuropathy, most commonly caused by diabetes. In approximately 25-50% of all people with peripheral neuropathy, the cause is unknown. These cases…
Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
We are doing this study to find out if the research drug known as Rozanolixizumab can have additional benefit for people who are already receiving IVIG( Intravenous Immune Globulin) treatment for CIDP, and to have further safety evaluation of the research drug as well. If you choose to be part of this research study, the following procedures will occur:…
Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
Charcot-Marie-Tooth type 1A (CMT1A) disease is a rare, slowly progressing and debilitating hereditary condition commonly causing weakness of muscles in the feet and lower parts of the legs. There is currently no approved drug to cure CMT1A disease, and the available treatments commonly target the pain and inflammation associated with the disease. In order…
Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
International GBS Outcome Study (IGOS) is a study of the Inflammatory Neuropathy Consortium (INC) and Peripheral Nerve Society (PNS) on disease course and outcome in Guillain-Barr syndrome (GBS). Guillian Barre syndrome is an autoimmune disorder affecting the peripheral nervous system, leading to paralysis and potential fatality if it progresses to involve…
Condition: Psychiatric Disorders / Anxiety
Investigator: Jonathan Posner, MD
Status: Closed
The goal of this study is to advance our understanding of how the brain processes emotion in adolescents. Adolescents with and without symptoms of anxiety are invited to participate. This study takes place over two days and includes an evaluation and a brain imaging session. Participants will be compensated up to $250. This study does not provide treatment.
Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
You are being considered to participate in this research study because you have type I or II diabetes with current treatment control and, you are experiencing painful diabetic peripheral neuropathy (DPN) in both lower extremities legs.The specific events that result in painful diabetic peripheral neuropathy are not well understood, but high blood sugar,…